Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB)

$1.19 +0.02 (+1.71 %)
(As of 02/23/2018 01:36 AM ET)
Previous Close$1.19
Today's Range$1.16 - $1.23
52-Week Range$1.06 - $3.07
Volume48,642 shs
Average Volume260,318 shs
Market Capitalization$18.50 million
P/E Ratio-1.11
Dividend YieldN/A
Beta0.85

About Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences logoCellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Debt-to-Equity RatioN/A
Current Ratio3.14%
Quick Ratio3.14%

Price-To-Earnings

Trailing P/E Ratio-1.11213913888655
Forward P/E Ratio-1.24
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.31 per share
Price / Book0.91

Profitability

Trailing EPS($1.07)
Net Income$-6,180,000.00
Net MarginsN/A
Return on Equity-108.18%
Return on Assets-91.41%

Miscellaneous

Employees15
Outstanding Shares15,810,000

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.01. View Cellectar Biosciences' Earnings History.

When will Cellectar Biosciences make its next earnings announcement?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:

  • Stephen Anthony Hill M.D., Chairman of the Board (Age 59)
  • James V. Caruso, President, Chief Executive Officer, Director (Age 58)
  • John P. Hamill CPA, Interim Chief Financial Officer (Age 53)
  • Cameron Szakacs Ph.D., Vice President - Clinical Development (Age 51)
  • Jarrod Longcor, Chief Business Officer (Age 44)
  • Frederick W. Driscoll, Director (Age 66)
  • Douglas J. Swirsky, Director (Age 48)
  • Stefan D. Loren Ph.D., Independent Director (Age 53)
  • John P. Neis, Independent Director (Age 61)

Who owns Cellectar Biosciences stock?

Cellectar Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Anson Funds Management LP (2.42%). Company insiders that own Cellectar Biosciences stock include James V Caruso, John Neis, Paul L Berns and Richard Hertzberg. View Institutional Ownership Trends for Cellectar Biosciences.

Who bought Cellectar Biosciences stock? Who is buying Cellectar Biosciences stock?

Cellectar Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Anson Funds Management LP. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso, John Neis and Paul L Berns. View Insider Buying and Selling for Cellectar Biosciences.

How do I buy Cellectar Biosciences stock?

Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of Cellectar Biosciences stock can currently be purchased for approximately $1.19.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $18.50 million. The biopharmaceutical company earns $-6,180,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]


MarketBeat Community Rating for Cellectar Biosciences (CLRB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellectar Biosciences (NASDAQ:CLRB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$2.70$2.70
Price Target Upside: N/AN/A117.74% upside117.74% upside

Cellectar Biosciences (NASDAQ:CLRB) Consensus Price Target History

Price Target History for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ:CLRB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$2.70N/AView Rating Details
12/21/2016Langenberg & CompanyInitiated CoverageBuy$2.70N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Cellectar Biosciences (NASDAQ:CLRB) Earnings History and Estimates Chart

Earnings by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ CLRB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.23)N/AView Earnings Details
11/9/2017Q3 2017($0.25)($0.26)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.24)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.23)($0.35)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.20)($0.43)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.40)($0.49)ViewN/AView Earnings Details
5/12/2016Q1 2016$0.91ViewN/AView Earnings Details
11/12/2015Q315($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.30)ViewListenView Earnings Details
5/21/2015Q115($0.30)ViewListenView Earnings Details
3/24/2015Q4 2014($2.20)ViewN/AView Earnings Details
11/11/2014Q3 2014($1.00)ViewN/AView Earnings Details
8/20/2014Q2 2014($6.60)ViewN/AView Earnings Details
5/14/2014Q1 2014($10.00)ViewN/AView Earnings Details
3/25/2014Q4 2013($8.00)($10.00)ViewN/AView Earnings Details
11/6/2013Q3 2013($10.00)($14.00)$92.67 millionViewN/AView Earnings Details
8/12/2013Q2 2013($10.00)($10.00)ViewN/AView Earnings Details
5/15/2013Q1 2013($8.00)($12.00)ViewN/AView Earnings Details
5/4/2012Q1 2012($12.00)($11.80)ViewN/AView Earnings Details
3/9/2012Q4 2011($12.00)ViewN/AView Earnings Details
11/7/2011Q3 2011($14.20)ViewN/AView Earnings Details
8/18/2011Q2 2011($20.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cellectar Biosciences (NASDAQ:CLRB) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS

Dividends

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cellectar Biosciences (NASDAQ CLRB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.17%
Institutional Ownership Percentage: 2.05%
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences (NASDAQ CLRB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017John NeisDirectorSell5,214$1.49$7,768.86View SEC Filing  
11/29/2016John NeisDirectorBuy333,333$1.49$496,666.17View SEC Filing  
10/31/2016Richard HertzbergInsiderSell21,000$2.03$42,630.00280,000View SEC Filing  
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.7647,548View SEC Filing  
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52117,371View SEC Filing  
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.006,000View SEC Filing  
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.005,000View SEC Filing  
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.004,000View SEC Filing  
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cellectar Biosciences (NASDAQ CLRB) News Headlines

Source:
DateHeadline
Cellectar Biosciences (CLRB) Presents At BIO CEO & Investor Conference - SlideshowCellectar Biosciences (CLRB) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:27 PM
Cellectar Biosciences to Present at the 2018 BIO CEO & Investor ConferenceCellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 8:55 AM
biotechstocks.com: 2 Biotech Stocks to Watch This Quarterbiotechstocks.com: 2 Biotech Stocks to Watch This Quarter
www.finanznachrichten.de - January 29 at 4:25 PM
2 Biotech Stocks to Watch This Quarter2 Biotech Stocks to Watch This Quarter
finance.yahoo.com - January 29 at 4:25 PM
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic CancersCellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
finance.yahoo.com - January 29 at 9:14 AM
How Much is Cellectar Biosciences Inc’s (NASDAQ:CLRB) CEO Getting Paid?How Much is Cellectar Biosciences Inc’s (NASDAQ:CLRB) CEO Getting Paid?
finance.yahoo.com - January 24 at 9:34 AM
Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor ConferenceCellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference
finance.yahoo.com - January 22 at 5:49 PM
Reviewing Veru (VERU) & Cellectar Biosciences (CLRB)Reviewing Veru (VERU) & Cellectar Biosciences (CLRB)
www.americanbankingnews.com - January 20 at 11:30 PM
Cellectar Biosciences (CLRB) Stock Rating Upgraded by Zacks Investment ResearchCellectar Biosciences (CLRB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 16 at 10:02 PM
Cellectar Biosciences to Participate at Biotech Showcase 2018 - GlobeNewswire (press release)Cellectar Biosciences to Participate at Biotech Showcase 2018 - GlobeNewswire (press release)
globenewswire.com - January 6 at 4:55 PM
 Brokerages Set $3.10 Target Price for Cellectar Biosciences Inc (CLRB) Brokerages Set $3.10 Target Price for Cellectar Biosciences Inc (CLRB)
www.americanbankingnews.com - January 5 at 1:40 PM
Cellectar Biosciences to Participate at Biotech Showcase 2018Cellectar Biosciences to Participate at Biotech Showcase 2018
finance.yahoo.com - January 4 at 9:49 AM
 Cellectar Biosciences, Inc. (CLRB) Given Average Recommendation of "Strong Buy" by Brokerages Cellectar Biosciences, Inc. (CLRB) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 21 at 7:48 AM
Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric CancersCellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers
finance.yahoo.com - December 14 at 10:00 AM
Is Cellectar Biosciences Inc (CLRB) Thriving Or Barely Surviving In The Healthcare Sector?Is Cellectar Biosciences Inc (CLRB) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - December 8 at 4:55 PM
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
finance.yahoo.com - December 6 at 10:02 AM
Zacks: Analysts Set $3.10 Target Price for Cellectar Biosciences, Inc. (CLRB)Zacks: Analysts Set $3.10 Target Price for Cellectar Biosciences, Inc. (CLRB)
www.americanbankingnews.com - December 5 at 11:30 AM
Cellectar Biosciences, Inc. (CLRB) Downgraded to "Sell" at Zacks Investment ResearchCellectar Biosciences, Inc. (CLRB) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 21 at 8:58 PM
Cellectar Biosciences to Present at the 10th Annual LD Micro Main EventCellectar Biosciences to Present at the 10th Annual LD Micro Main Event
finance.yahoo.com - November 20 at 6:23 PM
GlaxoSmithKline PLC (GSK) & Cellectar Biosciences (CLRB) Critical ReviewGlaxoSmithKline PLC (GSK) & Cellectar Biosciences (CLRB) Critical Review
www.americanbankingnews.com - November 20 at 5:24 PM
Edited Transcript of CLRB earnings conference call or presentation 10-Nov-17 1:00pm GMTEdited Transcript of CLRB earnings conference call or presentation 10-Nov-17 1:00pm GMT
finance.yahoo.com - November 11 at 11:16 AM
Cellectar Biosciences, Inc. (CLRB) Announces Quarterly  Earnings ResultsCellectar Biosciences, Inc. (CLRB) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 3:52 PM
Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance - GlobeNewswire (press release)Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance - GlobeNewswire (press release)
globenewswire.com - November 10 at 9:48 AM
Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate PerformanceCellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - November 9 at 8:15 PM
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple MyelomaCellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
finance.yahoo.com - November 7 at 10:21 PM
Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results ... - GlobeNewswire (press release)Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - November 4 at 7:21 AM
Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate PerformanceCellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
feeds.benzinga.com - November 2 at 9:21 AM
Cellectar Biosciences, Inc. (CLRB) to Release Earnings on ThursdayCellectar Biosciences, Inc. (CLRB) to Release Earnings on Thursday
www.americanbankingnews.com - November 2 at 1:50 AM
New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External RadiationNew Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation
finance.yahoo.com - October 30 at 4:02 PM
Analyzing Cellectar Biosciences (CLRB) & The CompetitionAnalyzing Cellectar Biosciences (CLRB) & The Competition
www.americanbankingnews.com - October 27 at 1:24 PM
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma - GlobeNewswire (press release)Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma - GlobeNewswire (press release)
globenewswire.com - October 25 at 6:49 PM
Cellectar Bio finalizes design of multiple dose fifth cohort in early-stage dose-escalation study of multiple myeloma candidate CLR 131; shares ahead 2%Cellectar Bio finalizes design of multiple dose fifth cohort in early-stage dose-escalation study of multiple myeloma candidate CLR 131; shares ahead 2%
seekingalpha.com - October 25 at 12:44 AM
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple MyelomaCellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
finance.yahoo.com - October 24 at 7:40 PM
Cellectar Biosciences (CLRB) Reports Additional Japanese Patent ... - StreetInsider.comCellectar Biosciences (CLRB) Reports Additional Japanese Patent ... - StreetInsider.com
www.streetinsider.com - October 18 at 4:03 AM
Cellectar Biosciences, Inc. (CLRB) Raised to Hold at Zacks Investment ResearchCellectar Biosciences, Inc. (CLRB) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - October 17 at 8:26 PM
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid TumorsCellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
finance.yahoo.com - October 17 at 6:00 PM
Head to Head Comparison: Adamis Pharmaceuticals Corporation (ADMP) vs. Cellectar Biosciences (CLRB)Head to Head Comparison: Adamis Pharmaceuticals Corporation (ADMP) vs. Cellectar Biosciences (CLRB)
www.americanbankingnews.com - October 17 at 2:08 PM
Reviewing Cellectar Biosciences (CLRB) and Its PeersReviewing Cellectar Biosciences (CLRB) and Its Peers
www.americanbankingnews.com - October 17 at 12:28 AM
Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering - GlobeNewswire (press release)Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - October 12 at 11:06 PM
Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct OfferingCellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering
finance.yahoo.com - October 12 at 6:06 PM
Cellectar Biosciences (CLRB), Pierre Fabre Extend Pact for Development of New Phospholipid Drug ConjugatesCellectar Biosciences (CLRB), Pierre Fabre Extend Pact for Development of New Phospholipid Drug Conjugates
www.streetinsider.com - October 11 at 6:46 PM
Cellectar Biosciences (CLRB), Pierre Fabre Extend Pact for Development of New Phospholipid Drug Conjugates - StreetInsider.comCellectar Biosciences (CLRB), Pierre Fabre Extend Pact for Development of New Phospholipid Drug Conjugates - StreetInsider.com
www.streetinsider.com - October 11 at 4:32 AM
Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug ConjugatesCellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
finance.yahoo.com - October 10 at 6:28 PM
Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-MarketCellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
finance.yahoo.com - October 10 at 6:28 PM
Analyzing Cellectar Biosciences (CLRB) and Its CompetitorsAnalyzing Cellectar Biosciences (CLRB) and Its Competitors
www.americanbankingnews.com - October 4 at 10:24 PM
Cellectar Biosciences (CLRB) & Its Rivals Critical ReviewCellectar Biosciences (CLRB) & Its Rivals Critical Review
www.americanbankingnews.com - October 2 at 2:22 AM
Cellectar Biosciences to Present at The MicroCap ConferenceCellectar Biosciences to Present at The MicroCap Conference
globenewswire.com - September 29 at 4:17 PM
Cellectar Biosciences (CLRB) Announces Cohort Four Data and Partial Response in R/R Multiple Myeloma Patient ... - StreetInsider.comCellectar Biosciences (CLRB) Announces Cohort Four Data and Partial Response in R/R Multiple Myeloma Patient ... - StreetInsider.com
www.streetinsider.com - September 28 at 12:26 AM
Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
www.nasdaq.com - September 27 at 7:25 PM
Cellectar Biosciences (CLRB) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowCellectar Biosciences (CLRB) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 7:25 PM

SEC Filings

Cellectar Biosciences (NASDAQ:CLRB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellectar Biosciences (NASDAQ:CLRB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellectar Biosciences (NASDAQ CLRB) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.